NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

399.00 4.50 (1.14%)

37.11% Gain from 52W Low

2.9M NSE+BSE Volume

NSE 02 Dec, 2025 3:31 PM (IST)

53,344.8

Market Cap

Market Leader

Beta 1Year

High Volatility

Analyst Buy

Axis Direct maintains its 'Buy' rating on Biocon, expects a revenue CAGR of 19.8% over FY26-27 See details

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

24 Sep 2018

399.00

1.14%

Favorable regulatory outcome enhances biosimilars prospects

Neutral: Biocon Ltd.

Motilal Oswal

24 September 2018 received a positive opinion from CHMP for its Neulasta biosimilar for the EU market. BIOS/Mylan also have in place the EU good manufacturing practices (GMP) certification for their drug product and drug substance facilities. Biocon/Mylan would be the fourth team to receive a positive opinion for Neulasta for the EU market. Accord (subsidiary of Intas Pharma) and Coherus received a positive opinion in July 2018, followed by Sandoz (Novartis division) and Cinfa Biotech in September 2018. The global market size of Neulasta is ~USD4.5b (as of CY17; ex-US sales USD600m). Separately, the drug product facility was inspected in April-May 2018 and received the Establishment Inspection Report (EIR) in June 2018. Successful inspections at both its facilities imply minimal regulatory hurdles for sales of pegfilgrastim biosimilar in the US market. BIOS/MYL, leading companies vying for approval in the regulated markets are Apotex, Sandoz, Coherus, Pfizer and Dr.

Biocon Ltd. has an average target of 388.00 from 4 brokers.

Biocon Ltd.

27 Jul 2018

399.00

1.14%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 20% YoY to | 1124 crore (I-direct estimate: | 1214 crore) mainly due to 35.5% YoY growth in Biologics to | 250 crore (Idirect estimate: | 239 crore) and 39.5% YoY growth in contract research to | 406 crore (I-direct estimate: | 425 crore) EBITDA margins increased 60 bps YoY to 21.2% (I-direct estimate: 20.7%) mainly due to lower R&D; spend. EBITDA grew 23.8% YoY to | 238 crore against I-direct estimates of | 251 crore Net profit grew 47.4% YoY to | 119.8 crore (I-direct estimate: | 127.6...

Axis Direct decreased Buy price target of Biocon Ltd. to 440.0 on 01 Dec, 2025.

Biocon Ltd.

05 Jun 2018

399.00

1.14%

Second biosimilar approval for Biocon-Mylan in six months

Neutral: Biocon Ltd.

Motilal Oswal

5 June 2018 Neulasta biosimilar version) was based on a comprehensive package of analytical, non-clinical and clinical data, which confirmed that the product is highly similar to Neulasta. Because of non-interchangability clause, BIOS/MYL would have to invest marketing efforts to garner business from this product. Other than BIOS/MYL, leading companies vying for approval in regulated markets are Apotex, Sandoz, Coherus, Pfizer and Dr Reddys. However, Apotex has not yet received approval for its BLA (biologic license application) version from USFDA. Coherus would be submitting the day-180 responses by the end of May and expects further opinion from advisory group CHMP (Committee for Medicinal Products for Human Use) on day-210, which is around end of June 2018. EU regulators are reviewing marketing authorization applications filed by BIOS/MYL, Sandoz and Cinfa Biotech. Specifically, BIOS/MYLs MAA was accepted in November 2017, Cinfa Biotechs in October 2017, and Sandoz filed in October 2017.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

30 Apr 2018

399.00

1.14%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues increased 26% YoY to | 1170 crore (I-direct estimate: | 1098 crore) mainly due to 48% YoY growth in Biologics to | 241 crore (I-direct estimate: | 179 crore) and 45% YoY growth in Syngene to | 409 crore (I-direct estimate: | 359 crore). EBITDA margins remained at 20%, however lower than I-direct estimates of 22.0% mainly due to lower gross margins led by change in product mix. EBITDA increased 24% YoY to | 233 crore...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

31 Jan 2018

399.00

1.14%

Result Update:Biocon

Buy: Biocon Ltd.

Axis Direct

Subdued revenue (up 1% YoY) and EBITDA (down 20% YoY on higher staff costs) were in line with estimates. Higher depreciation and lower other income pulled PAT down 46% YoY (11% lower than our estimate).

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

29 Jan 2018

399.00

1.14%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Biocon reported flat YoY revenues at | 1058 crore (I-direct estimate: | 1073 crore). Biopharmaceutical segment declined 9% YoY to 369...

Biocon Ltd. has an average target of 388.00 from 4 brokers.

Biocon Ltd.

24 Jan 2018

399.00

1.14%

Company Report:Biocon

Buy: Biocon Ltd.

Axis Direct

We believe sharing responsibilities for end-to-end development, manufacturing and global regulatory approvals for a number of products will ensure higher control and ownership. This also allows to develop higher number of molecules by leveraging on their talent pools and existing capabilities

Biocon Ltd. has an average target of 388.00 from 4 brokers.

Biocon Ltd.

07 Dec 2017

399.00

1.14%

Company Update:Biocon

Buy: Biocon Ltd.

Axis Direct

First biosimilar approval for Herceptin (Trastuzumab; ~USD 2.5 bn in US) for the treatment of cancer establishes Biocon as a global biosimilar player'. While Mylan-Biocon has settled with Roche for launch on a certain date.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

04 Dec 2017

399.00

1.14%

Biocon

Buy: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research In a positive development for Biocon, the USFDA has approved Mylan's Ogivri, a biosimilar of Herceptin (Trastuzumab-dkst) co-developed with Biocon. The approval comes on the heels of a strong recommendation for approval of Biocon/Mylan's biosimilar Trastuzumab by the USFDA Oncologic Drugs Advisory Committee (ODAC) by a 16-0 vote in support of eligible indications of the reference product, on July 13, 2017. Herceptin, manufactured by Roche, is used to treat certain breast cancers...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

03 Dec 2017, 12:00AM

399.00

1.14%

Biocon: Mylan/ Biocon received Trastuzumab approval in US

Neutral: Biocon Ltd.

Motilal Oswal

Mylan/ Biocon announced on Friday that US FDA approved Mylan's Ogivr (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab), co-developed with Biocon. Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US. Notably, Mylan is the only player which has settled for a launch date with innovator Roche. Mylan anticipates to be the first player to launch biosimilar version of Herceptin. Patent for Herceptin is expiring in mid-2019. Since Biocon has not filed this product through interchangeable route, it will not receive exclusivity...

Biocon Ltd. has an average target of 388.00 from 4 brokers.

Is Biocon Ltd. worth buying?

733 Votes:

Buy 74.9%

Sell 16.37%

Hold 8.73%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf